Different Functional and Microstructural Changes Depending on Duration of Mild Cognitive Impairment in Parkinson Disease

References

1. 1.↵
   2. Emre M,
   3. Aarsland D,
   4. Brown R, et al

   . Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007;22:1689–707; quiz 837 pmid:17542011

   CrossRefPubMedWeb of Science
2. 2.↵
   2. Litvan I,
   3. Aarsland D,
   4. Adler CH, et al

   . MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord 2011;26:1814–24 doi:10.1002/mds.23823 pmid:21661055

   CrossRefPubMed
3. 3.↵
   2. Adler CH,
   3. Caviness JN,
   4. Sabbagh MN, et al

   . Heterogeneous neuropathological findings in Parkinson's disease with mild cognitive impairment. Acta Neuropathol 2010;120:827–28 doi:10.1007/s00401-010-0744-4 pmid:20838798

   CrossRefPubMedWeb of Science
4. 4.↵
   2. Jellinger KA

   . Neuropathology in Parkinson's disease with mild cognitive impairment. Acta Neuropathol 2010;120:829–30; author reply 31 doi:10.1007/s00401-010-0755-1 pmid:20922398

   CrossRefPubMed
5. 5.↵
   2. Alves G,
   3. Brønnick K,
   4. Aarsland D, et al

   . CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry 2010;81:1080–86 doi:10.1136/jnnp.2009.199950 pmid:20547614

   Abstract/FREE Full Text
6. 6.↵
   2. Montine TJ,
   3. Shi M,
   4. Quinn JF, et al

   . CSF β(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord 2010;25:2682–85 doi:10.1002/mds.23287 pmid:20818673

   CrossRefPubMed
7. 7.↵
   2. Compta Y,
   3. Pereira JB,
   4. Rios J, et al

   . Combined dementia-risk biomarkers in Parkinson's disease: a prospective longitudinal study. Parkinsonism Relat Disord 2013;19:717–24 doi:10.1016/j.parkreldis.2013.03.009 pmid:23643469

   CrossRefPubMed
8. 8.↵
   2. Compta Y,
   3. Ibarretxe-Bilbao N,
   4. Pereira JB, et al

   . Grey matter volume correlates of cerebrospinal markers of Alzheimer-pathology in Parkinson's disease and related dementia. Parkinsonism Relat Disord 2012;18:941–47 doi:10.1016/j.parkreldis.2012.04.028 pmid:22595621

   CrossRefPubMed
9. 9.↵
   2. Compta Y,
   3. Parkkinen L,
   4. O'Sullivan SS, et al

   . Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? Brain 2011;134:1493–505 doi:10.1093/brain/awr031 pmid:21596773

   Abstract/FREE Full Text
10. 10.↵
    2. Ballard C,
    3. Ziabreva I,
    4. Perry R, et al

    . Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology 2006;67:1931–34 doi:10.1212/01.wnl.0000249130.63615.cc pmid:17159096

    Abstract/FREE Full Text
11. 11.↵
    2. Song SK,
    3. Lee JE,
    4. Park HJ, et al

    . The pattern of cortical atrophy in patients with Parkinson's disease according to cognitive status. Mov Disord 2011;26:289–96 doi:10.1002/mds.23477 pmid:21370255

    CrossRefPubMed
12. 12.↵
    2. Lee JE,
    3. Cho KH,
    4. Kim M, et al

    . The pattern of cortical atrophy in Parkinson's disease with mild cognitive impairment according to the timing of cognitive dysfunction. J Neurol 2012;259:469–73 doi:10.1007/s00415-011-6203-x pmid:21818688

    CrossRefPubMed
13. 13.↵
    2. Greicius MD,
    3. Srivastava G,
    4. Reiss AL, et al

    . Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci U S A 2004;101:4637–42 doi:10.1073/pnas.0308627101 pmid:15070770

    Abstract/FREE Full Text
14. 14.↵
    2. Katsuse O,
    3. Iseki E,
    4. Marui W, et al

    . Developmental stages of cortical Lewy bodies and their relation to axonal transport blockage in brains of patients with dementia with Lewy bodies. J Neurol Sci 2003;211:29–35 doi:10.1016/S0022-510X(03)00037-6 pmid:12767494

    CrossRefPubMedWeb of Science
15. 15.↵
    2. Bellucci A,
    3. Zaltieri M,
    4. Navarria L, et al

    . From alpha-synuclein to synaptic dysfunctions: new insights into the pathophysiology of Parkinson's disease. Brain Res 2012;1476:183–202 doi:10.1016/j.brainres.2012.04.014 pmid:22560500

    CrossRefPubMed
16. 16.↵
    2. Frisoni GB,
    3. Fox NC,
    4. Jack CR Jr., et al

    . The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol 2010;6:67–77 doi:10.1038/nrneurol.2009.215 pmid:20139996

    CrossRefPubMedWeb of Science
17. 17.↵
    2. Seibert TM,
    3. Murphy EA,
    4. Kaestner EJ, et al

    . Interregional correlations in Parkinson disease and Parkinson-related dementia with resting functional MR imaging. Radiology 2012;263:226–34 doi:10.1148/radiol.12111280 pmid:22371611

    CrossRefPubMed
18. 18.↵
    2. Tessitore A,
    3. Esposito F,
    4. Vitale C, et al

    . Default-mode network connectivity in cognitively unimpaired patients with Parkinson disease. Neurology 2012;79:2226–32 doi:10.1212/WNL.0b013e31827689d6 pmid:23100395

    Abstract/FREE Full Text
19. 19.↵
    2. Fox MD,
    3. Greicius M

    . Clinical applications of resting state functional connectivity. Front Syst Neurosci 2010;4:19 doi:10.3389/fnsys.2010.00019. eCollection 2010 pmid:20592951

    CrossRefPubMed
20. 20.↵
    2. Hughes AJ,
    3. Daniel SE,
    4. Kilford L, et al

    . Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–84 doi:10.1136/jnnp.55.3.181 pmid:1564476

    Abstract/FREE Full Text
21. 21.↵
    2. Tomlinson CL,
    3. Stowe R,
    4. Patel S, et al

    . Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010;25:2649–53 doi:10.1002/mds.23429 pmid:21069833

    CrossRefPubMedWeb of Science
22. 22.↵
    2. Beck AT,
    3. Ward CH,
    4. Mendelson M, et al

    . An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561–71 doi:10.1001/archpsyc.1961.01710120031004 pmid:13688369

    CrossRefPubMedWeb of Science
23. 23.↵
    2. Kang Y,
    3. Na DL

    . Seoul Neuropsychological Screening Battery. Incheon: Human Brain Research & Consulting Co; 2003
24. 24.↵
    2. Litvan I,
    3. Goldman JG,
    4. Troster AI, et al

    . Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012;27:349–56 doi:10.1002/mds.24893 pmid:22275317

    CrossRefPubMed
25. 25.↵
    2. Slotnick SD,
    3. Moo LR,
    4. Segal JB, et al

    . Distinct prefrontal cortex activity associated with item memory and source memory for visual shapes. Brain Res Cogn Brain Res 2003;17:75–82 doi:10.1016/S0926-6410(03)00082-X pmid:12763194

    CrossRefPubMed
26. 26.↵
    2. Kalaitzakis ME,
    3. Graeber MB,
    4. Gentleman SM, et al

    . Striatal beta-amyloid deposition in Parkinson disease with dementia. J Neuropathol Exp Neurol 2008;67:155–61 doi:10.1097/NEN.0b013e31816362aa pmid:18219254

    CrossRefPubMed
27. 27.↵
    2. Tsuboi Y,
    3. Uchikado H,
    4. Dickson DW

    . Neuropathology of Parkinson's disease dementia and dementia with Lewy bodies with reference to striatal pathology. Parkinsonism Relat Disord 2007;13(suppl 3):S221–24 doi:10.1016/S1353-8020(08)70005-1 pmid:18267239

    CrossRefPubMed
28. 28.↵
    2. Mattila PM,
    3. Rinne JO,
    4. Helenius H, et al

    . Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol 2000;100:285–90 doi:10.1007/s004019900168 pmid:10965798

    CrossRefPubMedWeb of Science
29. 29.↵
    2. Mattila PM,
    3. Röyttä M,
    4. Lönnberg P, et al

    . Choline acetytransferase activity and striatal dopamine receptors in Parkinson's disease in relation to cognitive impairment. Acta Neuropathol 2001;102:160–66 pmid:11563631

    PubMedWeb of Science
30. 30.↵
    2. Jellinger KA,
    3. Attems J

    . Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies? Acta Neuropathol 2006;112:253–60 pmid:16804711

    CrossRefPubMedWeb of Science
31. 31.↵
    2. Lee JE,
    3. Cho KH,
    4. Song SK, et al

    . Exploratory analysis of neuropsychological and neuroanatomical correlates of progressive mild cognitive impairment in Parkinson's disease. J Neurol Neurosurg Psychiatry 2014;85:7–16 doi:10.1136/jnnp-2013-305062 pmid:23828835

    Abstract/FREE Full Text
32. 32.↵
    2. Weintraub D,
    3. Dietz N,
    4. Duda JE, et al

    . Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease. Brain 2012;135:170–80 doi:10.1093/brain/awr277 pmid:22108576

    Abstract/FREE Full Text
33. 33.↵
    2. Zhou Y,
    3. Dougherty JH Jr.,
    4. Hubner KF, et al

    . Abnormal connectivity in the posterior cingulate and hippocampus in early Alzheimer's disease and mild cognitive impairment. Alzheimers Dement 2008;4:265–70 doi:10.1016/j.jalz.2008.04.006 pmid:18631977

    CrossRefPubMedWeb of Science
34. 34.↵
    2. Smith AD

    . Imaging the progression of Alzheimer pathology through the brain. Proc Natl Acad Sci U S A 2002;99:4135–37 pmid:11929987

    FREE Full Text
35. 35.↵
    2. Kövari E,
    3. Gold G,
    4. Herrmann FR, et al

    . Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson's disease. Acta Neuropathol 2003;106:83–88 pmid:12687392

    PubMed
36. 36.↵
    2. Churchyard A,
    3. Lees AJ

    . The relationship between dementia and direct involvement of the hippocampus and amygdala in Parkinson's disease. Neurology 1997;49:1570–76 pmid:9409348

    Abstract/FREE Full Text
37. 37.↵
    2. Kalaitzakis ME,
    3. Christian LM,
    4. Moran LB, et al

    . Dementia and visual hallucinations associated with limbic pathology in Parkinson's disease. Parkinsonism Relat Disord 2009;15:196–204 doi:10.1016/j.parkreldis.2008.05.007 pmid:18602855

    CrossRefPubMedWeb of Science
38. 38.↵
    2. Braak H,
    3. Del Tredici K,
    4. Rüb U, et al

    . Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197–211 pmid:12498954

    CrossRefPubMedWeb of Science
39. 39.↵
    2. Halliday G,
    3. Hely M,
    4. Reid W, et al

    . The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol 2008;115:409–15 doi:10.1007/s00401-008-0344-8 pmid:18231798

    CrossRefPubMedWeb of Science
40. 40.↵
    2. Robinson JL,
    3. Laird AR,
    4. Glahn DC, et al

    . The functional connectivity of the human caudate: an application of meta-analytic connectivity modeling with behavioral filtering. Neuroimage 2012;60:117–29 doi:10.1016/j.neuroimage.2011.12.010 pmid:22197743

    CrossRefPubMedWeb of Science
41. 41.↵
    2. Baggio HC,
    3. Segura B,
    4. Sala-Llonch R, et al

    . Cognitive impairment and resting-state network connectivity in Parkinson's disease. Hum Brain Mapp 2015;36:199–212 doi:10.1002/hbm.22622 pmid:25164875

    CrossRefPubMed
42. 42.↵
    2. Amboni M,
    3. Tessitore A,
    4. Esposito F, et al

    . Resting-state functional connectivity associated with mild cognitive impairment in Parkinson's disease. J Neurol 2015;262:425–34 doi:10.1007/s00415-014-7591-5 pmid:25428532

    CrossRefPubMed